IVIG has been used for treatment in patients who have refractory disease. Reports about its effectiveness conflict. Findings from continuing clinical assessment and muscle enzyme abnormalities guide the duration of treatment. Significant morbidity is associated with these diseases, as is significant morbidity caused by the drugs used in treatment. Survival is less likely in women and African American patients.
Most patients improve with therapy.
The immunopathologic and inflammatory differences between dermatomyositis, polymyositis and sporadic inclusion body myositis. Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. However, as medical science is constantly changing and human error is always possible , the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use.